$RVVTF News! Revive Therapeutics Announces Initiat
Post# of 24762
![Avatar](/images/ProfileImages/982093748_22164_no_avatar_available.jpg)
TORONTO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has initiated the development of a next generation formulation of Bucillamine for the potential treatment of public health medical emergencies including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.
https://finance.yahoo.com/news/revive-therape...00575.html
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)